Bulletin
Investor Alert

Pfizer Inc.

NYS: PFE

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Pfizer Inc.

After Hours

 --Quotes are delayed by 20 min

Oct 23, 2020, 7:59 p.m.

PFE
/zigman2/quotes/202877789/composite

$

38.12

Change

-0.06 -0.16%

Volume

Volume 3.76m

Quotes are delayed by 20 min

/zigman2/quotes/202877789/composite

Previous close

$ 37.43

$ 38.18

Change

+0.75 +2.00%

Day low

Day high

$37.65

$38.29

Open

52 week low

52 week high

$27.88

$40.97

Open

Company Description

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commerc...

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Valuation

P/E Current

13.05

P/E Ratio (with extraordinary items)

14.84

P/E Ratio (without extraordinary items)

13.66

Price to Sales Ratio

4.30

Price to Book Ratio

3.43

Price to Cash Flow Ratio

17.66

Enterprise Value to EBITDA

13.17

Enterprise Value to Sales

5.15

Total Debt to Enterprise Value

0.20

Efficiency

Revenue/Employee

586,070.00

Income Per Employee

184,247.00

Receivables Turnover

6.18

Total Asset Turnover

0.32

Liquidity

Current Ratio

0.88

Quick Ratio

0.66

Cash Ratio

0.26

Profitability

Gross Margin

71.52

Operating Margin

27.28

Pretax Margin

34.17

Net Margin

31.44

Return on Assets

9.95

Return on Equity

25.71

Return on Total Capital

12.69

Return on Invested Capital

16.56

Capital Structure

Total Debt to Total Equity

84.71

Total Debt to Total Capital

45.85

Total Debt to Total Assets

31.93

Long-Term Debt to Equity

58.62

Long-Term Debt to Total Capital

31.73

Officers and Executives

Name Age Officer Since Title
Dr. Albert Bourla 57 2005 Director, Chief Executive & Operating Officer
Mr. Frank A. D'Amelio 61 2007 Chief Financial Officer & EVP-Business Operations
Ms. Lidia L. Fonseca 50 - Chief Technology Officer & EVP
Dr. Monika A. Vnuk - 2008 Vice President-Worldwide Business Development
Dr. Margaret McLoughlin 56 2014 Executive Director-World Wide Business Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/06/2020 Ronald E. Blaylock
Director 		1,000   Acquisition at $38.62 per share. 38,620
08/06/2020 Ronald E. Blaylock
Director 		1,000   Acquisition at $38.69 per share. 38,690
08/06/2020 Ronald E. Blaylock
Director 		1,500   Acquisition at $38.51 per share. 57,765
08/06/2020 Ronald E. Blaylock
Director 		2,500   Acquisition at $38.56 per share. 96,400
08/06/2020 Ronald E. Blaylock
Director 		3,000   Acquisition at $38.55 per share. 115,650
08/06/2020 Ronald E. Blaylock
Director 		4,000   Acquisition at $38.49 per share. 153,960
06/05/2020 Jennifer B. Damico
SVP & Controller 		2,181   Disposition at $36.13 per share. 78,799
05/18/2020 Mikael Dolsten
President R&D 		24,242   Disposition at $37.79 per share. 916,105
05/18/2020 Mikael Dolsten
President R&D 		17,357   Disposition at $37.78 per share. 655,747
05/18/2020 Mikael Dolsten
President R&D 		16,840   Disposition at $37.8 per share. 636,552
05/18/2020 Mikael Dolsten
President R&D 		14,727   Disposition at $37.77 per share. 556,238
05/18/2020 Mikael Dolsten
President R&D 		9,700   Disposition at $37.75 per share. 366,175
05/18/2020 Mikael Dolsten
President R&D 		6,470   Disposition at $37.81 per share. 244,630
05/18/2020 Mikael Dolsten
President R&D 		5,517   Disposition at $37.76 per share. 208,321
05/18/2020 Mikael Dolsten
President R&D 		500   Disposition at $37.82 per share. 18,910
04/29/2020 John D. Young
Group President 		7,910   Gift at $0 per share. 0
04/29/2020 Douglas M. Lankler
Executive Vice President 		57,099   Disposition at $37.83 per share. 2,160,055
04/29/2020 Douglas M. Lankler
Executive Vice President 		7,901   Disposition at $38.01 per share. 300,317
04/29/2020 Rady A. Johnson
Executive Vice President 		13,125   Disposition at $38.36 per share. 503,475
04/29/2020 Dawn Rogers
Executive Vice President 		13,000   Disposition at $38.13 per share. 495,690
04/29/2020 Jennifer B. Damico
SVP & Controller 		2,181   Disposition at $38.35 per share. 83,641
02/28/2020 Frank A. D'Amelio
Executive Vice President 		89,721   Derivative/Non-derivative trans. at $36.45 per share. 3,270,330
02/28/2020 Frank A. D'Amelio
Executive Vice President 		41,113   Derivative/Non-derivative trans. at $33.42 per share. 1,373,996
02/28/2020 John D. Young
Group President 		51,943   Derivative/Non-derivative trans. at $36.45 per share. 1,893,322
02/28/2020 John D. Young
Group President 		23,802   Derivative/Non-derivative trans. at $33.42 per share. 795,462
02/28/2020 Albert Bourla
Chairman & CEO; Director 		17,118   Derivative/Non-derivative trans. at $36.45 per share. 623,951
02/28/2020 Albert Bourla
Chairman & CEO; Director 		6,701   Derivative/Non-derivative trans. at $33.42 per share. 223,947
02/28/2020 Mikael Dolsten
President R&D 		39,446   Derivative/Non-derivative trans. at $33.42 per share. 1,318,285
02/28/2020 Sally Susman
Executive Vice President 		47,221   Derivative/Non-derivative trans. at $36.45 per share. 1,721,205
02/28/2020 Sally Susman
Executive Vice President 		23,517   Derivative/Non-derivative trans. at $33.42 per share. 785,938
02/28/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		14,166   Derivative/Non-derivative trans. at $36.45 per share. 516,350
02/28/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		4,503   Derivative/Non-derivative trans. at $33.42 per share. 150,490
02/28/2020 Alexander Roderick MacKenzie
Executive Vice President 		19,597   Derivative/Non-derivative trans. at $36.45 per share. 714,310
02/28/2020 Alexander Roderick MacKenzie
Executive Vice President 		9,760   Derivative/Non-derivative trans. at $33.42 per share. 326,179
02/28/2020 Douglas M. Lankler
Executive Vice President 		20,069   Derivative/Non-derivative trans. at $36.45 per share. 731,515
02/28/2020 Douglas M. Lankler
Executive Vice President 		9,197   Derivative/Non-derivative trans. at $33.42 per share. 307,363
02/28/2020 Rady A. Johnson
Executive Vice President 		8,264   Derivative/Non-derivative trans. at $36.45 per share. 301,222
02/28/2020 Rady A. Johnson
Executive Vice President 		2,627   Derivative/Non-derivative trans. at $33.42 per share. 87,794
02/28/2020 Michael Goettler
Group President 		11,805   Derivative/Non-derivative trans. at $36.45 per share. 430,292
02/28/2020 Michael Goettler
Group President 		4,419   Derivative/Non-derivative trans. at $33.42 per share. 147,682
02/28/2020 Dawn Rogers
Executive Vice President 		9,208   Derivative/Non-derivative trans. at $36.45 per share. 335,631
02/28/2020 Dawn Rogers
Executive Vice President 		3,014   Derivative/Non-derivative trans. at $33.42 per share. 100,727
02/28/2020 Frank A. D'Amelio
Executive Vice President 		173,675   Derivative/Non-derivative trans. at $27.37 per share. 4,753,484
02/28/2020 John D. Young
Group President 		100,548   Derivative/Non-derivative trans. at $27.37 per share. 2,751,998
02/28/2020 Albert Bourla
Chairman & CEO; Director 		33,135   Derivative/Non-derivative trans. at $27.37 per share. 906,904
02/28/2020 Sally Susman
Executive Vice President 		91,408   Derivative/Non-derivative trans. at $27.37 per share. 2,501,836
02/28/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		27,422   Derivative/Non-derivative trans. at $27.37 per share. 750,540
02/28/2020 Alexander Roderick MacKenzie
Executive Vice President 		37,934   Derivative/Non-derivative trans. at $27.37 per share. 1,038,253
02/28/2020 Douglas M. Lankler
Executive Vice President 		38,848   Derivative/Non-derivative trans. at $27.37 per share. 1,063,269
02/28/2020 Rady A. Johnson
Executive Vice President 		15,996   Derivative/Non-derivative trans. at $27.37 per share. 437,810
02/28/2020 Michael Goettler
Group President 		22,852   Derivative/Non-derivative trans. at $27.37 per share. 625,459
02/28/2020 Dawn Rogers
Executive Vice President 		17,824   Derivative/Non-derivative trans. at $27.37 per share. 487,842
02/26/2020 Frank A. D'Amelio
Executive Vice President 		110,626   Derivative/Non-derivative trans. at $36.8 per share. 4,071,036
02/26/2020 Frank A. D'Amelio
Executive Vice President 		22,314   Derivative/Non-derivative trans. at $34.72 per share. 774,742
02/26/2020 Frank A. D'Amelio
Executive Vice President 		12,537   Derivative/Non-derivative trans. at $34.72 per share. 435,284
02/26/2020 John D. Young
Group President 		110,626   Derivative/Non-derivative trans. at $36.8 per share. 4,071,036
02/26/2020 John D. Young
Group President 		22,314   Derivative/Non-derivative trans. at $34.72 per share. 774,742
02/26/2020 John D. Young
Group President 		12,485   Derivative/Non-derivative trans. at $34.72 per share. 433,479
02/26/2020 Albert Bourla
Chairman & CEO; Director 		67,605   Derivative/Non-derivative trans. at $36.8 per share. 2,487,864
02/26/2020 Albert Bourla
Chairman & CEO; Director 		7,121   Derivative/Non-derivative trans. at $34.72 per share. 247,241
02/26/2020 Mikael Dolsten
President R&D 		22,314   Derivative/Non-derivative trans. at $34.72 per share. 774,742
02/26/2020 Mikael Dolsten
President R&D 		15,478   Derivative/Non-derivative trans. at $34.72 per share. 537,396
02/26/2020 Sally Susman
Executive Vice President 		55,313   Derivative/Non-derivative trans. at $36.8 per share. 2,035,518
02/26/2020 Sally Susman
Executive Vice President 		10,384   Derivative/Non-derivative trans. at $34.72 per share. 360,532
02/26/2020 Sally Susman
Executive Vice President 		6,556   Derivative/Non-derivative trans. at $34.72 per share. 227,624
02/26/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		18,438   Derivative/Non-derivative trans. at $36.8 per share. 678,518
02/26/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		1,943   Derivative/Non-derivative trans. at $34.72 per share. 67,460
02/26/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		1,290   Derivative/Non-derivative trans. at $34.72 per share. 44,788
02/26/2020 Alexander Roderick MacKenzie
Executive Vice President 		8,104   Derivative/Non-derivative trans. at $34.72 per share. 281,370
02/26/2020 Alexander Roderick MacKenzie
Executive Vice President 		7,984   Derivative/Non-derivative trans. at $34.72 per share. 277,204
02/26/2020 Douglas M. Lankler
Executive Vice President 		67,605   Derivative/Non-derivative trans. at $36.8 per share. 2,487,864
02/26/2020 Douglas M. Lankler
Executive Vice President 		15,691   Derivative/Non-derivative trans. at $34.72 per share. 544,791
02/26/2020 Douglas M. Lankler
Executive Vice President 		7,121   Derivative/Non-derivative trans. at $34.72 per share. 247,241
02/26/2020 Rady A. Johnson
Executive Vice President 		25,506   Derivative/Non-derivative trans. at $36.8 per share. 938,620
02/26/2020 Rady A. Johnson
Executive Vice President 		3,569   Derivative/Non-derivative trans. at $34.72 per share. 123,915
02/26/2020 Rady A. Johnson
Executive Vice President 		2,682   Derivative/Non-derivative trans. at $34.72 per share. 93,119
02/26/2020 Angela Hwang
Group President 		11,063   Derivative/Non-derivative trans. at $36.8 per share. 407,118
02/26/2020 Angela Hwang
Group President 		1,166   Derivative/Non-derivative trans. at $34.72 per share. 40,483
02/26/2020 Michael Goettler
Group President 		15,365   Derivative/Non-derivative trans. at $36.8 per share. 565,432
02/26/2020 Michael Goettler
Group President 		1,906   Derivative/Non-derivative trans. at $34.72 per share. 66,176
02/26/2020 Michael Goettler
Group President 		1,266   Derivative/Non-derivative trans. at $34.72 per share. 43,955
02/26/2020 Dawn Rogers
Executive Vice President 		11,524   Derivative/Non-derivative trans. at $36.8 per share. 424,083
02/26/2020 Dawn Rogers
Executive Vice President 		1,250   Derivative/Non-derivative trans. at $34.72 per share. 43,400
02/26/2020 Frank A. D'Amelio
Executive Vice President 		45,566   Award at $0 per share. 0
02/26/2020 John D. Young
Group President 		45,566   Award at $0 per share. 0
02/26/2020 Mikael Dolsten
President R&D 		45,566   Award at $0 per share. 0
02/26/2020 Sally Susman
Executive Vice President 		22,783   Award at $0 per share. 0
02/26/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		3,797   Award at $0 per share. 0
02/26/2020 Alexander Roderick MacKenzie
Executive Vice President 		17,087   Award at $0 per share. 0
02/26/2020 Alexander Roderick MacKenzie
Executive Vice President 		21,202   Award at $0 per share. 0
02/26/2020 Douglas M. Lankler
Executive Vice President 		34,175   Award at $0 per share. 0
02/26/2020 Rady A. Johnson
Executive Vice President 		10,506   Award at $0 per share. 0
02/26/2020 Michael Goettler
Group President 		3,164   Award at $0 per share. 0
02/26/2020 Frank A. D'Amelio
Executive Vice President 		144,928   Derivative/Non-derivative trans. at $34.59 per share. 5,013,059
02/26/2020 John D. Young
Group President 		144,928   Derivative/Non-derivative trans. at $34.59 per share. 5,013,059
02/26/2020 Albert Bourla
Chairman & CEO; Director 		88,567   Derivative/Non-derivative trans. at $34.59 per share. 3,063,532
02/26/2020 Sally Susman
Executive Vice President 		72,464   Derivative/Non-derivative trans. at $34.59 per share. 2,506,529
02/26/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		24,155   Derivative/Non-derivative trans. at $34.59 per share. 835,521
02/26/2020 Douglas M. Lankler
Executive Vice President 		88,567   Derivative/Non-derivative trans. at $34.59 per share. 3,063,532
02/26/2020 Rady A. Johnson
Executive Vice President 		33,414   Derivative/Non-derivative trans. at $34.59 per share. 1,155,790
02/26/2020 Angela Hwang
Group President 		14,493   Derivative/Non-derivative trans. at $34.59 per share. 501,312
02/26/2020 Michael Goettler
Group President 		20,129   Derivative/Non-derivative trans. at $34.59 per share. 696,262
02/26/2020 Dawn Rogers
Executive Vice President 		15,097   Derivative/Non-derivative trans. at $34.59 per share. 522,205
02/23/2020 Loretta V. Cangialosi
Sr. Vice President, Controller 		1,574   Derivative/Non-derivative trans. at $35.72 per share. 56,223
02/23/2020 Angela Hwang
Group President 		1,409   Derivative/Non-derivative trans. at $35.72 per share. 50,329
02/23/2020 Michael Goettler
Group President 		2,116   Derivative/Non-derivative trans. at $35.72 per share. 75,583
02/23/2020 Dawn Rogers
Executive Vice President 		1,015   Derivative/Non-derivative trans. at $35.72 per share. 36,255
01/31/2020 Lidia L. Fonseca
Executive Vice President 		6,043   Derivative/Non-derivative trans. at $37.24 per share. 225,041
01/30/2020 Scott Gottlieb
Director 		1,000   Acquisition at $37 per share. 37,000
12/29/2019 John D. Young
Group President 		9,676   Derivative/Non-derivative trans. at $39.32 per share. 380,460
/news/latest/company/us/pfe

MarketWatch News on PFE

  2. Why Snap’s Surge Is Good News for Social Media

    5:51 p.m. Oct. 23, 2020

    - Max Cherney

  3. These Emerging Market Stocks Can Rival U.S. Tech Giants

    4:55 p.m. Oct. 23, 2020

    - Reshma Kapadia

  4. Johnson & Johnson stock rises Friday, still underperforms market

    4:25 p.m. Oct. 23, 2020

    - MarketWatch Automation

  7. Stock Futures Flat After Final Debate Ends

    11:11 p.m. Oct. 22, 2020

    - Connor Smith

  8. Johnson & Johnson stock outperforms market on strong trading day

    4:25 p.m. Oct. 22, 2020

    - MarketWatch Automation

  9. FDA Coronavirus Meeting Aims to Reassure Public

    1:59 p.m. Oct. 22, 2020

    - Bill Alpert

  10. Glaxo Vaccines Target Another Viral Threat

    12:04 p.m. Oct. 22, 2020

    - Bill Alpert

  12. Johnson & Johnson stock falls Wednesday, underperforms market

    4:25 p.m. Oct. 21, 2020

    - MarketWatch Automation

  13. Participant in AstraZeneca Covid Vaccine Trial Dies

    2:16 p.m. Oct. 21, 2020

    - Ben Walsh

  15. Johnson & Johnson stock rises Tuesday, still underperforms market

    4:26 p.m. Oct. 20, 2020

    - MarketWatch Automation

  16. Gold scores back-to-back gains, settles at highest in over a week

    3:28 p.m. Oct. 20, 2020

    - Myra P. Saefong

  19. These are the 3 best dividend yield investments for 2021

    10:11 a.m. Oct. 20, 2020

    - Michael Brush

  21. Loading more headlines...
/news/nonmarketwatch/company/us/pfe

Other News on PFE

  1. To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Competitors

    12:00 a.m. Today

    - Joseph Walker

  2. Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase

    12:33 p.m. Oct. 23, 2020

    - Gregory Zuckerman

  3. Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase

    12:33 p.m. Oct. 23, 2020

    - Gregory Zuckerman

  4. FDA getting cold feet on EUA nod for COVID-19 vaccines

    11:25 a.m. Oct. 23, 2020

    - Seeking Alpha

  5. Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    10:05 a.m. Oct. 23, 2020

    - Zacks.com

  6. Understanding Pfizer's Unusual Options Activity

    9:16 a.m. Oct. 23, 2020

    - benzinga.com

  8. 7 Earnings Reports to Watch Next Week

    7:45 a.m. Oct. 23, 2020

    - InvestorPlace.com

  9. Is a Beat in Store for Glaxo (GSK) This Earnings Season?

    7:28 a.m. Oct. 23, 2020

    - Zacks.com

  10. Wall Street Breakfast: Employees Or Contractors?

    6:59 a.m. Oct. 23, 2020

    - Seeking Alpha

  11. Pfizer (PFE) Gets a Buy Rating from Mizuho Securities

    7:55 p.m. Oct. 22, 2020

    - SmarterAnalyst

  13. Covid-19 Vaccines: What’s Coming and When?

    7:06 p.m. Oct. 22, 2020

    - Ana Rivas

  14. New U.S. Coronavirus Cases Surpass 60,000 for Second Day

    6:14 p.m. Oct. 22, 2020

    - Talal Ansari

  16. Coronavirus Hype Is Pushing Novavax to Unrealistic Highs

    1:55 p.m. Oct. 22, 2020

    - InvestorPlace.com

  17. Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?

    1:31 p.m. Oct. 22, 2020

    - InvestorPlace.com

  19. Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    10:15 a.m. Oct. 22, 2020

    - Zacks.com

  20. Investors Pump Billions into Biotech Startups

    6:00 a.m. Oct. 22, 2020

    - Brian Gormley

  21. Loading more headlines...

At a Glance

Pfizer Inc.

235 East 42nd Street

New York, New York 10017-5755

Phone

1 2127332323

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

View SEC Filings

Revenue

$51.75B

Net Income

$16.27B

Employees

88,300

Annual Report for PFE

/news/pressrelease/company/us/pfe

Press Releases on PFE

  2. Diagnostic Testing Capabilities Improve in the Face of Global Turmoil

    9:00 a.m. Oct. 23, 2020

    - PR Newswire - PRF

  21. Loading more headlines...
Link to MarketWatch's Slice.